🤖 AI Agents - Research Evidence Access

🤖 AI Agents - Research Evidence Access

This article discusses how Elicit API and MCP server address the need for reliable evidence in AI agent research. It highlights their capability to search extensive academic and clinical trial databases.

Key Points:

• AI agents require dependable evidence for research tasks.

• Elicit API and MCP server provide access to research data.

• The system supports searching 138 million papers.

• It also indexes 545,000 clinical trials.

🔗 Resources:

Image

💡 Environmental Data - Severe Heat Risk

This article provides an update on current heat risk levels in Phoenix and Las Vegas. Both cities are experiencing severe heat, according to CDC tiers.

Key Points:

• Phoenix and Las Vegas are at the CDC's most severe heat-risk tier.

• Phoenix temperatures are near 110°F.

• Las Vegas temperatures are near 106°F.

🔗 Resources:

Image

✨ Claude AI - Enhanced Voice Mode

This article details the updates to Claude's voice mode, which now integrates with more capable models and external tools. It also expands language support across various platforms.

Key Points:

• Voice mode operates with Claude Opus and Sonnet models.

• Claude can access connected tools like email and calendar during conversations.

• The feature supports additional languages including Spanish, French, Hindi, and Japanese.

• Voice mode is available in public beta across mobile, desktop, and web platforms.

🚀 Implementation:

1. Download the Claude mobile application.
2. Tap the sound wave icon within the app to initiate a voice conversation.

🔗 Resources:

Image

Image

💡 Environmental Data - Grass Pollen Allergy

This article reports on the current prevalence of grass pollen allergy across the Southern United States. Bermuda grass is identified as a primary allergen in the region.

Key Points:

• Grass pollen allergy affects approximately 45 million people in the South.

• Bermuda grass is the main contributor to pollen levels.

• The affected area spans from Georgia to Texas.

🔗 Resources:

Image

💡 Techbio - Drug Discovery Education

This article introduces "Valence at the Whiteboard," a new video series designed to explain core concepts in modern drug discovery. The series aims to educate those new to the techbio field.

Key Points:

• "Valence at the Whiteboard" is a new educational video series.

• The series focuses on central concepts in modern drug discovery.

• Researchers explain topics through whiteboard drawings.

• The first video has been released.

🤖 Oncology - FDA Approval for Zidesamtinib

This article reports on the US FDA approval of Jideytro (zidesamtinib) for ROS1-positive non-small cell lung cancer. The approval applies to previously treated patients.

Key Points:

• Jideytro (zidesamtinib) received US FDA approval.

• It treats ROS1-positive non-small cell lung cancer.

• The approval is for patients who have been previously treated.

🔗 Resources:

Image

🤖 Myeloma Treatment - CART and BsAb Therapies

This article presents a table summarizing available CAR T-cell therapy (CART) and Bispecific Antibody (BsAb) treatments for earlier lines in Myeloma. It clarifies the current approval status of certain therapies.

Key Points:

• A table outlines available CART and BsAb therapies for Myeloma.

• Talquetamab is not yet approved for earlier treatment lines.

• Elranatamab and Linvo have approval for later treatment lines.

🔗 Resources:

Image

Image

💡 Oncology - EGFR+ Lung Cancer Treatment Gaps

This article identifies five key unaddressed areas in the treatment of EGFR-positive lung cancer. These gaps cover therapy selection, toxicity management, and long-term patient outcomes.

Key Points:

• Determining the necessity of combination therapy remains a question.

• Choosing between frontline combination therapies requires further clarity.

• The sufficiency of TKI monotherapy is under review.

• Strategies for reducing toxicity without compromising efficacy are needed.

• Evaluating earlier treatment to improve long-term outcomes is a priority.

🔗 Resources:

Image

⭐️ Support

If you liked reading this report, please star ⭐️ this repository and follow me on Github ↗, 𝕏 (previously known as Twitter) ↗ to help others discover these resources and regular updates.